August 2024 Content Release Copied

08/29/20242024 ContentContent releasePhysician, Clinical, Admin, Billing

Clinical Profile Documentation

AJCC Version 8 Staging

This release contains updated TNM values, Staging Groups, and Template functionality to align with AJCC version 8 conditions for:

  • Sarcoma of soft tissue, Malignant neoplasm of connective tissue

Users will see updated values and descriptions for Primary Tumor Type (T), Regional Lymph Nodes (N), and Distance Metastasis (M), documentation points for Sarcoma, Soft Tissue.

The following value is no longer available:

  • T1a, T1b, T2a, T2b
  • Nx
  • M0, M1

The following documentation points now have updated descriptions:

  • T1, T2, T3, T4
  • N0, N1
  • cM0, cM1, pM1

The staging calculator will display updated Stage values based on the changes to the staging groups. The added content does not affect previous charting documented on existing patients. A summary table is provided below.

All previous charting is brought forward during a subsequent visit, just as it did prior to this release.

Tumor Type Node Metastasis Stage
cM1 IV
pM1 IV
T4 N1 cM0 III
T4 N0 cM0 III
T3 N1 cM0 III
T3 N0 cM0 III
T2 N1 cM0 III
T2 N0 cM0 II
T1 N1 cM0 III
T1 N0 cM0 I
T0 NX cM0 Unknown
T1 NX cM0 Unknown
T2 NX cM0 Unknown
T3 NX cM0 Unknown
TX N0 cM0 Unknown
TX N1 cM0 Unknown
TX NX cM0 Unknown
T0 N1 cM0 Unknown
T0 N0 cM0 Unknown

Problems

Additions

Added items are available for documentation in Problems and appear in the Charge Capture Report (CCR). Additional ICD-10 codes* may be displayed to present the surrounding nodes.

Lab Analytes & Panels

Additions

  • ADAMTS13 inhibitor titer, BU
  • ADAMTS13 profile interpretation
  • ADAMTS13 profile interpretation (reflex test) panel
  • Alb/Creat ratio, mg/g creat
  • Alpha-Globin common test panel
  • Altera panel
  • BCR-ABL1 kinase domain mutation analysis
  • BCR/ABL, tyrosine kinase inhib resist, mutation screen panel
  • BCRABL fusion (210, 190, 205, 230)
  • CLL/MCL prognosis: IgHV mutation analysis by NGS panel
  • Ag specimen type
  • Coccidioides Ag interpretation
  • Coccidioides Ag quant, ng/mL
  • Copeptin proAVP panel
  • Copeptin proAVP, pmol/L
  • CSF aerobic/anaerobic culture, reflex to PCR (lumbar puncture only)
  • CSF aerobic/anaerobic culture, reflex to PCR (lumbar puncture only) panel
  • Eosinophils, smear, urine
  • Haystack MRD(TM) baseline blood received date
  • Haystack MRD(TM) baseline date of diagnosis
  • Haystack MRD(TM) baseline EDTA blood collection date
  • Haystack MRD(TM) baseline hospital discharge date
  • Haystack MRD(TM) baseline location of specimen
  • Haystack MRD(TM) baseline minimal residual disease
  • Haystack MRD(TM) baseline MRD blood collection date
  • Haystack MRD(TM) baseline next steps
  • Haystack MRD(TM) baseline panel
  • Haystack MRD(TM) baseline prism order ID
  • Haystack MRD(TM) baseline recorded diagnosis
  • Haystack MRD(TM) baseline report ID
  • Haystack MRD(TM) baseline result details
  • Haystack MRD(TM) baseline specimen location fax
  • Haystack MRD(TM) baseline specimen location phone
  • Haystack MRD(TM) baseline surgery date
  • Haystack MRD(TM) baseline tumor collection date
  • Haystack MRD(TM) baseline tumor received date
  • Haystack MRD(TM) baseline tumor source
  • Haystack MRD(TM) baseline tumor specimen ID
  • Haystack MRD(TM) monitoring panel
  • Herpes virus 6 DNA PCR, qn, log copies/mL
  • Herpesvirus 7 DNA, qn real time, log copies/mL
  • IHC single ab with interpretation panel
  • Immediate PT mix panel
  • Immediate PT mix, sec
  • Invitae hereditary thrombophilia panel
  • Onkosight advanced 523 gene NGS with pierianDx interpretation panel
  • Paraneoplastic autoantibody evaluation panel, CSF
  • PCA-2, CSF
  • PDGFRA sequencing interpretation summary
  • PDGFRA sequencing methods
  • PDGFRA sequencing panel
  • PDGFRA sequencing references 1
  • PDGFRA sequencing report footer
  • PDGFRA sequencing result
  • Potassium, urine, 24 hour panel
  • Protein/creatinine ratio, urine, mg/mg creat
  • Signatera + Altera panel
  • Signatera initial panel
  • Signatera subsequent panel
  • Susceptibility AFB, slow grower
  • Tempus xM (NeXT Personal Dx) KIT panel
  • Tempus xM KIT panel

Medications

Additions

  • AB521 invest Oral
  • Biest Topical Cream
  • BNT327 invest IV
  • DS-7300A invest IV
  • FID-007 invest IV
  • Hyaluronic Acid Vaginal Cream
  • IBRX-042 invest subcutaneous
  • IDE196 invest Oral
  • MRTX0902 invest Oral
  • Testosterone Sublingual
  • TL118 invest Oral
  • TORL-2-307-ADC invest IV

Updates

Medication Update
BI 1810632 invest Oral Added new name Zongertinib invest
Crovalimab-akkz IV
  • Updated sigs and instructions
  • Changed default form
  • Added maximum single dose
Crovalimab-akkz Subcutaneous
  • Updated sigs and instructions
  • Changed default form
  • Added maximum single dose
Donanemab-azbt IV
  • Updated sigs and instructions
  • Changed default form
Infliximab IV (Remicade) Added new sig options
Infliximab-axxq IV (Avsola) Added new sig options
Infliximab-abda IV (Renflexis) Added new sig options
Infliximab-dyyb IV (Inflectra) Added new sig options
Pemetrexed IV Added maximum single dose
SGN-B6A invest IV Added new sig; 1.8 mg/kg AIBW intravenously once
Sodium Hyaluronate Vaginal Added brand Revaree and Revaree Plus
STP938 invest IV Added new name Dencatistat invest

Regimen Library

Topical Diclofenac for HFS Prevention in Capecitabine Regimens

To improve ease of ordering and serve as a reminder for prescribers, the Collaborative Care Committee (CCC) voted to add and precheck a topical diclofenac prescription for hand-foot syndrome (HFS) prevention in capecitabine-containing regimens. All regimens will be updated with the August content release.

Additions

Regimen Name Diagnosis
Crovalimab-akkz IV D1 fb SQ D2,8,15,22 fb Q28D (PNH) Paroxysmal Nocturnal Hemoglobinuria
Donanemab-azbt Q28D Alzheimer’s disease
Epcoritamab-bysp (Epkinly) SQ D1,8,15,22 fb D1,15 fb D1 Q28D (FL) Lymphoma, Non-Hodgkin (NHL) (Parent)
Exemestane Q30D (Ovarian, Uterine) Ovarian and Primary Peritoneal Cancer; Fallopian Tube Cancer; Uterine Cancer (Parent)
Ifosfamide Bolus D1-5 Q21D (Uterine Sarcoma) Uterine Cancer (Parent)
Leuprolide Q28D (Ovarian, Uterine) Fallopian Tube Cancer, Ovarian and Primary Peritoneal Cancer, Uterine Cancer (Parent)
Methotrexate HD + Rituximab IV D3 + Temozolomide PO Q14D (Induction) Brain Tumor (Parent)
Venetoclax D1-14 + Azacitidine D1-7 Q28D (MDS) Myelodysplastic Syndrome (MDS)
Vorasidenib Q30D Brain Tumor (Parent)

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference updates, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

  • Amyloidosis
  • Anal Cancer (Parent)
  • Arthritis, Rheumatoid
  • Bile Duct Cancer (Parent)
  • Bladder Cancer
  • Breast Cancer
  • Colon Cancer
  • Esophageal Cancer (Parent)
  • Fallopian Tube Cancer
  • Gallbladder Cancer
  • Gastric Cancer
  • Hepatocellular Carcinoma (HCC)
  • Lung Cancer, Non-small Cell (NSCLC)
  • Lung Cancer, Small Cell (SCLC)
  • Lymphoma, Non-Hodgkin (NHL) (Parent)
  • Melanoma, Skin
  • Multiple Myeloma (MM)
  • Neuroendocrine Tumor, Carcinoid (Parent)
  • Ovarian and Primary Peritoneal Cancer
  • Pancreatic Cancer
  • Pancreatic Cancer, Carcinoid/Neuroendocrine
  • Rectal Cancer
  • Renal Cell Carcinoma (RCC)
  • Renal Pelvis and Ureter Cancer
  • Renal Cell Carcinoma (RCC)
  • Sarcoma, Soft Tissue (Parent)
  • Thyroid Cancer (Parent)
  • Urethral Cancer
  • Uterine Cancer (Parent)

Renames

Previous Name New Name
Daratumumab SQ Q7D (Part 1 of 3) Daratumumab SQ C1-2 D1,8,15,22 fb C3-6 D1,15 fb C7-12 D1 Q28D
Doxorubicin 60 mg/m2 CIV D1-3 + Ifosfamide 1500 mg/m2 D1-4 Q21D (Uterine Sarcoma) Doxorubicin 25 mg/m2 D1-3 + Ifosfamide 3000 mg/m2 CIV D1-3 Q21D (Uterine Sarcoma)
Epcoritamab-bysp SQ D1,8,15,22 fb D1,15 fb D1 Q28D Epcoritamab-bysp (Epkinly) SQ D1,8,15,22 fb D1,15 fb D1 Q28D (DLBCL)
Fulvestrant Q28D (Breast) Fulvestrant Q28D (Breast, Uterine Sarcoma)

Billing & HCPCS Codes

Updates

Medication HCPCS Codes
Adalimumab-ryvk Subcutaneous Auto-Injector J3590 per 40 mg
Adalimumab-ryvk Subcutaneous J3590 per 40 mg
Afamitresgene autoleucel IV J9999 per 10 x 10e9 MAGE-A4 TCR pos T cells
Crovalimab-akkz IV J3590 per 340 mg
Crovalimab-akkz Subcutaneous J3590 per 340 mg
Donanemab-azbt IV J0175 per 2 mg

NDC – HCPCS Crosswalk

Additions

Effective July 1, 2024.

Medication (Brand) HCPCS Code NDC
Cyclophosphamide IV J9073 per 5 mg
  • 75907-0191-02
  • 75907-0190-07
  • 75907-0189-35